As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
Clinical trial NCT04656002 · UNKNOWN
Trial details
- NCT number
- NCT04656002
- Sponsor
- Samsung Medical Center
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2023-12-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.